Hideyuki Iwamoto Selected Research

Hideyuki Iwamoto Research Topics

Disease

9	Type 2 Diabetes Mellitus (MODY) 04/2024 - 09/2019
3	Body Weight (Weight, Body) 03/2024 - 01/2021
3	Hypothyroidism 01/2023 - 01/2022
3	Diabetes Mellitus 10/2022 - 01/2021
3	Hyperglycemia 10/2022 - 01/2022
2	Inflammation (Inflammations) 03/2024 - 03/2024
2	Atherosclerosis 03/2024 - 12/2020
2	Insulin Resistance 03/2024 - 10/2022
2	Pituitary ACTH Hypersecretion 10/2022 - 01/2022
2	Cushing Syndrome 10/2022 - 01/2022
2	Diabetes Complications 10/2022 - 01/2022
1	Fatty Liver 03/2024
1	Obesity 03/2024
1	COVID-19 03/2023
1	Hyperaldosteronism (Conn Syndrome) 01/2023
1	Chronic Thyroiditis 01/2023
1	Neoplasms (Cancer) 01/2023
1	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 10/2022
1	Acidosis 10/2022
1	Hypersensitivity (Allergy) 10/2022
1	Disease Progression 07/2022
1	Diabetic Neuropathies (Diabetic Neuropathy) 01/2022
1	Aortic Aneurysm (Aneurysm, Aortic) 01/2022
1	Aortic Dissection 01/2022
1	Infections 07/2021
1	Thiamine Deficiency 01/2021
1	Edema (Dropsy) 01/2021
1	Dyslipidemias (Dyslipidemia) 12/2020
1	Hypertension (High Blood Pressure) 12/2020
1	Sarcopenia 12/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 09/2019
1	Overweight 09/2019

Drug/Important Bio-Agent (IBA)

5	Insulin (Novolin)FDA Link 04/2024 - 01/2022
3	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 01/2021
2	Blood Glucose (Blood Sugar)IBA 03/2024 - 09/2019
2	Biomarkers (Surrogate Marker)IBA 03/2024 - 12/2020
2	Thyroxine (Levothyroxine)FDA LinkGeneric 01/2023 - 01/2022
2	Thyroid HormonesIBA 01/2023 - 01/2022
2	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2023
2	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 01/2023 - 01/2022
2	Hydrocortisone (Cortisol)FDA LinkGeneric 10/2022 - 01/2022
1	cyclopropapyrroloindoleIBA 04/2024
1	C-PeptideIBA 04/2024
1	anagliptinIBA 03/2024
1	imegliminIBA 03/2024
1	ChemokinesIBA 03/2024
1	Sodium-Glucose Transporter 2 InhibitorsIBA 03/2024
1	Apolipoproteins E (ApoE)IBA 03/2024
1	Streptozocin (Streptozotocin)FDA Link 03/2024
1	InflammasomesIBA 03/2024
1	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 03/2024
1	Dipeptidyl-Peptidase IV InhibitorsIBA 03/2024
1	Hemoglobins (Hemoglobin)IBA 03/2024
1	semaglutideIBA 01/2024
1	dulaglutideIBA 01/2024
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2024
1	Immunoglobulin G (IgG)IBA 03/2023
1	AutoantibodiesIBA 01/2023
1	anti-thyroglobulinIBA 01/2023
1	AntibodiesIBA 01/2023
1	Iodide Peroxidase (Deiodinase)IBA 01/2023
1	LigandsIBA 01/2023
1	Programmed Cell Death 1 ReceptorIBA 01/2023
1	Furosemide (Lasix)FDA LinkGeneric 01/2023
1	Adrenocorticotropic Hormone (ACTH)FDA Link 10/2022
1	Indicators and Reagents (Reagents)IBA 10/2022
1	Dexamethasone (Maxidex)FDA LinkGeneric 10/2022
1	KetonesIBA 10/2022
1	Insulin AntibodiesIBA 10/2022
1	InsulinsIBA 07/2022
1	insulin aspart drug combination insulin degludecIBA 07/2022
1	Long-Acting Insulin (Insulin, Long Acting)FDA Link 07/2022
1	insulin degludecIBA 07/2022
1	Insulin Glargine (Lantus)FDA Link 07/2022
1	Insulin SecretagoguesIBA 07/2022
1	Glucagon (Glukagon)FDA Link 01/2022
1	NAD (NADH)IBA 01/2022
1	Anti-Bacterial Agents (Antibiotics)IBA 07/2021
1	Thiamine (Aneurin)FDA Link 01/2021
1	Fursultiamin (Fursultiamine)IBA 01/2021
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 12/2020

Therapy/Procedure

5	Therapeutics 04/2024 - 01/2022
5	Glycemic Control 03/2024 - 09/2019
1	Ambulatory Care (Outpatient Care) 03/2023
1	Aftercare (After-Treatment) 01/2022